Phosphorylated p53 TAD Binding Assay for Senescent Cell Apoptosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved assays and methods to identify effective treatments that selectively induce apoptosis in senescent cells, which are linked to degenerative diseases and cancer involving the mammalian protein p53.
Innovation Solution
A method for identifying improved anti-senescence compounds by detecting specific binding to the transcription activation domain (TAD) of the p53 protein, particularly in the presence of phosphorylated amino acids, and using retro-inverso peptides derived from FOXO4 protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genetic clearance of senescent cells is used to delay aging and limit dysfunction, then parameters of aging are decreased and fitness is improved, but therapeutic applicability is poor due to the genetic approach required
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to achieve the effect of genetic clearance without requiring genetic modification. These compounds selectively target and eliminate senescent cells through pharmacological intervention, bridging the gap between the high efficacy of genetic approaches and the practical needs of therapeutic applications.
Solution Approach 2:
The patent replaces the genetic/molecular biology-based clearance mechanism with a pharmacological/chemical mechanism. Instead of using genetic tools to clear senescent cells, small molecule compounds are used to induce selective apoptosis in senescent cells, making the approach therapeutically applicable while maintaining efficacy.
2Productivity
If assays are developed to identify anti-senescence compounds, then effective treatments can be found, but the complexity of detecting and measuring phosphorylation states and specific binding increases
Solution Approach 1:
The patent focuses the assay on specific local features: phosphorylation at particular amino acid residues (Ser15, Ser20, Ser46, Thr55) in the TAD domain of p53. By concentrating on these specific phosphorylation sites rather than analyzing the entire protein, the assay achieves high productivity in identifying effective compounds while managing complexity through targeted measurement.
Solution Approach 2:
The patent uses changes in binding parameters (binding affinity, binding specificity) as phosphorylation states change to identify anti-senescence compounds. By monitoring how compound binding to p53-TAD varies with phosphorylation status, the assay efficiently identifies effective treatments without requiring complex multi-parameter analysis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively identifies compounds that enhance binding to phosphorylated p53, thereby inducing apoptosis in senescent cells, and is useful for treating conditions like cancer and age-related disorders.
Implementation Method 1
detecting the binding of said compound in the presence of at least one phosphorylated amino acid in the transcription activation domain (TAD) domain of mammalian protein p53
Data Source
AI summary
The present invention relates to a method, in particular an in vitro method, for identifying an improved anti-senescence compound based on detecting the binding of said compound in the presence of at least one phosphory lated amino acid in the transcription activation domain (TAD) domain of mammalian protein p53. The present invention further relates to a method, in particular an in vitro method, for monitoring an anti-senescence treatment or prophylaxis in a mammalian subject in need thereof, based on detecting the amount of phosphorylation of amino acids in the TAD and/or C-terminal region of the mammalian p53 protein in a biological sample obtained from said subject and/or detecting the amount and/or co-localization with phosphorylated p53 of the promyelocytic leukemia protein (PML) bodies in a biological sample obtained from said subject. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof. Finally, improved anti-senescence compounds or pharmaceutical compositions are provided.